For research use only
| Cat No. | ABC-TC3899 |
| Product Type | Immune Cells |
| Cell Type | NK Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human Mobilized Peripheral Blood CD56+ NK Cells from AcceGen, positively selected immune cells for cytotoxicity, immunology, and translational studies.
Human Mobilized Peripheral Blood CD56+ NK Cells are lymphocytes isolated from mobilized peripheral blood mononuclear cells using immunomagnetic CD56 Micro-Beads. CD56+ NK cells play critical roles in immune surveillance, directly lysing virally infected or malignant cells via antibody-dependent cellular cytotoxicity (ADCC) and cytokine secretion. They also modulate adaptive immunity by interacting with dendritic cells and T cells. Defective NK activity contributes to viral persistence and impaired tumor surveillance. Key surface markers include CD56. To ensure the quality of these primary cells, repeated freeze-thaw cycles are not recommended due to the fragile nature of these cells. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | Human Mobilized Peripheral Blood CD56+ NK Cells, Mobilized NK Cells, CD56+ Natural Killer Cells, mPB NK Cells |
| Species | Human |
| Cat.No | ABC-TC3899 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | NK Cell |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Immune Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Mobilized Peripheral Blood CD56+ NK Cells have significant therapeutic potential, particularly in cancer immunotherapy and infectious disease treatment. Due to their innate ability to recognize and kill malignant or virus-infected cells without prior sensitization, they are being explored in adoptive cell therapy (ACT) for hematological malignancies and solid tumors.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).